

Serial No:  
Filed:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

J1059 U.S. PTO  
09/995217  
11/27/01

APPLICATION OF: Andrew L. Pearlman  
SERIAL NO: 09/537,004 GROUP ART UNIT: 3737  
FILED: March 28, 2000 EXAMINER: Manuel, G.  
BATCH NO. H43  
CUSTOMER NO.: 27162  
FOR: TISSUE CHARACTERIZATION BASED ON IMPEDANCE  
IMAGES AND ON IMPEDANCE MEASUREMENTS  
ATTY/DKT NO.: 701030-11

Box Issue Fee  
Commissioner for Patents  
Washington, DC 20231

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

\_\_\_\_ §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.  
No fee or statement is required.

\_\_\_\_ §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

\_\_\_\_ The statement as specified in 37 CFR §1.97(e) set out below; OR

\_\_\_\_ The fee of \$230.00 under 37 CFR §1.17(p).

Serial No:  
Filed:

X §1.97(d)

This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND  
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$180.00 set out in 37 CFR §1.17(i).

X §1.97(e)


The undersigned Attorney hereby states that:

X each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or

— no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.



#113106

Respectfully submitted,  
Andrew L. Pearlman

William Squire  
Reg. No. 25,378  
CARELLA, BYRNE BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
Six Becker Farm Road  
Roseland, NJ 07068  
Tel: (973)994-1700  
Fax: (973)994-1744

BUT filed on or before payment of the Issue Fee; AND  
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$180.00 set out in 37 CFR §1.17(i).

\_\_\_\_ §1.97(e) The undersigned Attorney hereby states that:

- \_\_\_\_ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;  
or
- \_\_\_\_ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

Items 1 – 41 and 43 – 59 on Form 1449 were cited in the parent application and no copies are being provided herewith.

Items 43 – 45 and 64 – 66 were cited in a corresponding foreign filed application and copies are enclosed.

Items 42 and 63 were not previously cited and copies are enclosed.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

Respectfully submitted,  
Andrew L. Pearlman



William Squire  
Reg. No. 25.378

CARELLA, BYRNE BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN

Six Becker Farm Road  
Roseland, NJ 07068

Tel: (973)994-1700

Fax: (973)994-1744

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: Andrew L. Pearlman  
SERIAL NO: Not assigned GROUP ART UNIT: Not assigned  
FILED: Herewith EXAMINER: Not assigned  
CUSTOMER NO.: 27162  
FOR: Tissue Characterization Based on Impedance Images and on  
Impedance Measurements  
ATTY/DKT NO.: 701030-13

J1059 U.S. PTO  
09/995217  
11/27/01

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

- ☒ §1.97(b) This Information Disclosure Statement is filed:
- (1) Within three months of the filing date of a national application; OR
  - (2) Within three months of the date of entry of the national stage of an international application; OR
  - (3) Before the mailing of a first Office Action on the merits. No fee or statement is required.

☐ §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

☐ The statement as specified in 37 CFR §1.97(e) set out below; OR

☐ The fee of \$180.00 under 37 CFR §1.17(p).

☐ §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;